Kwality Pharmaceuticals (539997) investor relations material

Executive summary

• Achieved record quarterly and annual revenues in FY26, with Q4 revenue of ₹157.11 crore, up 35.8% year-over-year, and full-year consolidated revenue of ₹503 crore, up 36% from FY25.

• EBITDA margin expanded to 24% (up 200 bps), and PAT grew 69% YoY to ₹67.34 crore, with PAT margin rising to 13.4%.

• Cleared multiple international regulatory audits, received a credit rating upgrade to BBB+, and expanded global presence through participation in over 15 international exhibitions.

• Launched large-scale bioequivalence programs and advanced biologics pipeline, including successful pre-clinical outcomes for Erythropoietin.

Financial highlights

• Q4 FY26 revenue: ₹157.11 crore (up 35.8% YoY); FY26 consolidated revenue: ₹503 crore (up 36% YoY).

• EBITDA margin: 24% in FY26 vs 22% in FY25; PAT: ₹67.34 crore (up 69% YoY); PAT margin: 13.4% vs 10.8% in FY25.

• Standalone profit after tax for FY26: ₹67.35 crore; EPS: ₹64.90.

• Cash and cash equivalents at year-end: ₹68.28 lakh (standalone), ₹73.64 lakh (consolidated).

Outlook and guidance

• FY27 revenue guidance: ₹650 crore; PAT guidance: ₹100 crore, with potential upside depending on international approvals and commercialization.

• Targeting ₹1,000 crore topline by FY29, aiming to double revenues in three years.